

Department of Health and Human Services
National Institutes of Health
National Heart, Lung, and Blood Institute
309th Meeting of the
National Heart, Lung, and Blood Advisory Council
October 30, 2024

Hybrid Format
31 Center Drive
Building 31, C Wing, 6th Floor, Room A/B
Bethesda, MD 20894

Agenda

Closed Portion – 8:00 a.m. – 9:20 a.m.

This portion of the meeting is being closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2). Council members are required to absent themselves from the room during the review of any application if their presence would constitute or appear to constitute a conflict of interest.

I. Welcome

Dr. Gary H. Gibbons, Director, National Heart, Lung, and Blood Institute

II. Administrative Announcements

Dr. Charisee A. Lamar, Director, Division of Extramural Research Activities, NHLBI

III. Consideration of Grant Applications

NHLBI-Wide

- [RFA-HL-23-004: NHLBI Outstanding Investigator Award \(OIA\) \(R35\) Clinical Trial Optional](#) Dr. Simhan Danthi
- [RFA-HL-23-005: NHLBI Emerging Investigator Award \(EIA\) \(R35 Clinical Trial Optional\)](#) Dr. Simhan Danthi
- [RFA-HL-23-008: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, & Sleep Disorders and Diseases \(R44 Clinical Trial Optional\)](#) Dr. Stephanie Davis
- [RFA-HL-23-009: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, & Sleep Disorders and Diseases \(R44 Clinical Trial Optional\)](#) Dr. Stephanie Davis

- RFA-HL-23-010: Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) Dr. Mike Pieck
- RFA-HL-23-011: Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed) Dr. Mike Pieck
- RFA-HL-23-012: Catalyze: Product Definition for Small Molecules and Biologics – Preliminary Product/Lead Series Identification (R33 – Clinical Trial Not Allowed) Dr. Mike Pieck
- RFA-HL-23-013: Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 – Clinical Trial Not Allowed) Dr. Mike Pieck
- RFA-HL-23-014: Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33) Dr. Mike Pieck
- RFA-HL-25-001: Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed) Dr. Li-Shin Huang

Division of Cardiovascular Sciences

Advanced Technologies and Surgery Branch
Atherothrombosis and Coronary Artery Disease Branch

Dr. David Goff
Dr. Kathleen Fenton
Dr. Jue Chen *acting*

- PAR-21-343: Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) Dr. David W. Schopfer
- RFA-HL-23-006: Stimulating Access to Research in Residency (StARR) (R38) Dr. David W. Schopfer

Clinical Applications and Prevention Branch
Epidemiology Branch
Heart Developmental and Structural Diseases Branch
Heart Failure and Arrhythmias Branch
Vascular Biology and Hypertension Branch

Dr. Nicole Redmond
Dr. Yuling Hong
Dr. Kristin Burns
Dr. Renee Wong
Dr. Zorina Galis

Division of Lung Diseases

Acute and Infectious Lung Diseases Branch
Lung Development and Pediatric Diseases Branch
Obstructive Lung Diseases Branch

Dr. Gus Matute-Bello
Dr. Guofei Zhou
Dr. Marrah Lachowicz-Scroggins
Dr. Lisa Postow

- [RFA-HL-24-005: Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients \(R03 Clinical Trial Optional\)](#)

Dr. Qing Lu

Restrictive and Vascular Lung Diseases Branch
National Center on Sleep Disorders Research

Dr. John Sheridan
Dr. Marishka Brown

Division of Blood Diseases and Resources

Blood Epidemiology and Clinical Therapeutics Branch
Molecular Cellular and Systems Blood Science Branch
Translational Blood Science and Resources Branch

Dr. Julie Panepinto
Dr. Traci Mondoro *acting*
Dr. Allison Gillaspay
Dr. Andrei Kindzelski

- [RFA-HL-23-003: Physician Scientist Transition to Independence in Blood Science Research \(R00 - Clinical Trial Optional\)](#)

Dr. Lisbeth Welniak

Center for Translation Research and Implementation Science

Health Inequities and Global Health Branch
Implementation Science Branch
Translation Research Branch

Dr. George A. Mensah
Dr. Cara C. Lewis
Dr. Cara C. Lewis
Dr. George A. Mensah

Adjournment

Break

Open Portion – 9:30 a.m. – 5:00 p.m.

Videocasting: <https://www.nhlbi.nih.gov/about/advisory-and-peer-review-committees/advisory-council>

IV. Welcome

Dr. Gary H. Gibbons, Director, National Heart, Lung, and Blood Institute

V. Administrative Announcements

Dr. Charisee A. Lamar, Director, Division of Extramural Research Activities, NHLBI

VI. Director's Report

Dr. Gary H. Gibbons, Director, National Heart, Lung, and Blood Institute

VII. "Women's Health Research: The Time is Now"

Dr. Janine Austin Clayton, Director, Office of Research on Women's Health, NIH

VIII. Workgroup Report

Dr. Tina V. Hartert, Member, National Heart, Lung, and Blood Advisory Council

Lunch

IX. Decision Lens Refresher Training

X. NHLBI Concepts

Dr. Charisee A. Lamar and NHLBI Program Division Directors

XI. Closing Remarks

Adjournment

Future Meeting Dates

2025

February 4 (Tuesday - Virtual)
June 11 (Wednesday – In-person)
August 20 (grant review only - Virtual)
October 28 (Tues. w/ BEE – In-person)
October 29 (Wednesday – In-person)

2026

February 10 (Tuesday - Virtual)
June 9 (Tuesday – In-person)
August 18 (grant review only - Virtual)
October 27 (Tues. w/ BEE – In-person)
October 28 (Wednesday – In-person)